As seasonal influenza continues to pose a significant global health challenge, the necessity for effective vaccination strategies, particularly in pediatric populations, becomes increasingly important. Understanding the cost-effectiveness of different influenza vaccines can significantly influence healthcare decision-making. This study systematically examines the economic implications of vaccinating individuals under 18, comparing the efficacy and costs associated with trivalent inactivated vaccines (TIV), quadrivalent inactivated vaccines (QIV), and live-attenuated vaccines in reducing disease transmission.
Methodological Approach
The researchers performed an extensive literature review across major scientific databases, such as PubMed, Web of Science, Scopus, and Cochrane, analyzing publications from 2013 to 2024. This comprehensive search targeted studies involving individuals younger than 18 years to decipher the cost-effectiveness of diverse vaccination strategies. A structured Excel spreadsheet facilitated the extraction and categorization of relevant data for deeper analysis. Understanding which type of vaccine offers superior cost benefits, alongside how seasonal vaccination influences both healthcare costs and health outcomes, remained the focal points of inquiry.
Key Findings
The analysis included 33 carefully selected studies adhering to predetermined inclusion and exclusion criteria. The findings overwhelmingly underscore that pediatric vaccination is economically favorable. However, variations emerged based on epidemiological factors, age groups, and demographic characteristics, emphasizing the need for localized analysis in vaccine policy implementation. The type of vaccine and its contextual use case play crucial roles in optimizing the financial and health impacts, highlighting local health considerations as a critical aspect of policy design.
Inferences drawn include:
- Quadrivalent vaccines exhibit higher overall cost-effectiveness compared to their trivalent and live-attenuated counterparts.
- Local health outcomes improve significantly with tailored vaccine strategies.
- Economic burden on healthcare systems can be reduced substantially through informed vaccine selection.
Strategies promoting pediatric influenza vaccination provide measurable reductions in transmission rates and associated healthcare costs. Integrating quadrivalent vaccines displays superior cost benefits, positioning them as a preferred choice. Nonetheless, decision-makers must consider unique local economic conditions and population health profiles to tailor optimal vaccination strategies. By focusing on strategic vaccine implementation, public health officials can achieve enhanced disease prevention while navigating the economic constraints of healthcare systems. Adopting a data-driven approach to vaccination policies thus becomes imperative for bolstering public health resilience against seasonal influenza impacts.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
